Cargando…
The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients
INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing tho...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314558/ https://www.ncbi.nlm.nih.gov/pubmed/34311790 http://dx.doi.org/10.1186/s42238-021-00091-z |
_version_ | 1783729576244936704 |
---|---|
author | Jackson, Melissa A. Brown, Amanda L. Johnston, Jennifer Clancy, Richard McGregor, Iain Bruno, Raimondo Lintzeris, Nick Montebello, Mark Luksza, Jennifer Bowman, Jenny Phung, Nghi Allsop, Dave Dunlop, Adrian J. |
author_facet | Jackson, Melissa A. Brown, Amanda L. Johnston, Jennifer Clancy, Richard McGregor, Iain Bruno, Raimondo Lintzeris, Nick Montebello, Mark Luksza, Jennifer Bowman, Jenny Phung, Nghi Allsop, Dave Dunlop, Adrian J. |
author_sort | Jackson, Melissa A. |
collection | PubMed |
description | INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing those who report ever using SCRAs with those who have never used SCRAs. METHODS: A questionnaire orally administered in person to a convenience sample of 154 cannabis treatment service clients from New South Wales, Australia (71% male, median age 35) collected information regarding cannabis and SCRA use including motivations, effects and health-related consequences of use, demographics, other substance use and overall health. Demographic profiles and between-group differences were explored. McNemar tests compared effects of SCRA and cannabis. Logistic regression analysis determined predictors of SCRA use. RESULTS: Half (53%) reported lifetime SCRA use; 20% reported previous-month use. The SCRA + cannabis group displayed greater polysubstance use and psychological distress. Reduced dependence on cannabis but higher levels of other substance use may predict SCRA use. Although curiosity motivated initial SCRA consumption, perceived psychoactive strength drove continued use. SCRAs appear to induce more negative side-effects than cannabis. Of the SCRA + cannabis group, 27% sought medical assistance for SCRA use. Most (90%) preferred cannabis to SCRAs, citing superior safety, effects and consistency of cannabis. CONCLUSIONS: Among clients seeking treatment for cannabis use, SCRA use was relatively common, although not a preferred substance. Hazardous substance use and poor mental health characterised SCRA consumers, highlighting the need for continued monitoring by researchers and treatment providers of SCRA consumption in populations who use substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42238-021-00091-z. |
format | Online Article Text |
id | pubmed-8314558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-83145582021-07-28 The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients Jackson, Melissa A. Brown, Amanda L. Johnston, Jennifer Clancy, Richard McGregor, Iain Bruno, Raimondo Lintzeris, Nick Montebello, Mark Luksza, Jennifer Bowman, Jenny Phung, Nghi Allsop, Dave Dunlop, Adrian J. J Cannabis Res Original Research INTRODUCTION: Despite decreasing consumption by general populations, use of synthetic cannabinoid receptor agonists (SCRAs) persists in some marginalised groups, including those who use other substances. This article explores SCRA consumption in an Australian cannabis treatment sample, comparing those who report ever using SCRAs with those who have never used SCRAs. METHODS: A questionnaire orally administered in person to a convenience sample of 154 cannabis treatment service clients from New South Wales, Australia (71% male, median age 35) collected information regarding cannabis and SCRA use including motivations, effects and health-related consequences of use, demographics, other substance use and overall health. Demographic profiles and between-group differences were explored. McNemar tests compared effects of SCRA and cannabis. Logistic regression analysis determined predictors of SCRA use. RESULTS: Half (53%) reported lifetime SCRA use; 20% reported previous-month use. The SCRA + cannabis group displayed greater polysubstance use and psychological distress. Reduced dependence on cannabis but higher levels of other substance use may predict SCRA use. Although curiosity motivated initial SCRA consumption, perceived psychoactive strength drove continued use. SCRAs appear to induce more negative side-effects than cannabis. Of the SCRA + cannabis group, 27% sought medical assistance for SCRA use. Most (90%) preferred cannabis to SCRAs, citing superior safety, effects and consistency of cannabis. CONCLUSIONS: Among clients seeking treatment for cannabis use, SCRA use was relatively common, although not a preferred substance. Hazardous substance use and poor mental health characterised SCRA consumers, highlighting the need for continued monitoring by researchers and treatment providers of SCRA consumption in populations who use substances. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42238-021-00091-z. BioMed Central 2021-07-26 /pmc/articles/PMC8314558/ /pubmed/34311790 http://dx.doi.org/10.1186/s42238-021-00091-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Jackson, Melissa A. Brown, Amanda L. Johnston, Jennifer Clancy, Richard McGregor, Iain Bruno, Raimondo Lintzeris, Nick Montebello, Mark Luksza, Jennifer Bowman, Jenny Phung, Nghi Allsop, Dave Dunlop, Adrian J. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title | The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title_full | The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title_fullStr | The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title_full_unstemmed | The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title_short | The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients |
title_sort | use and effects of synthetic cannabinoid receptor agonists by new south wales cannabis treatment clients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314558/ https://www.ncbi.nlm.nih.gov/pubmed/34311790 http://dx.doi.org/10.1186/s42238-021-00091-z |
work_keys_str_mv | AT jacksonmelissaa theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT brownamandal theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT johnstonjennifer theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT clancyrichard theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT mcgregoriain theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT brunoraimondo theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT lintzerisnick theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT montebellomark theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT lukszajennifer theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT bowmanjenny theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT phungnghi theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT allsopdave theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT dunlopadrianj theuseandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT jacksonmelissaa useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT brownamandal useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT johnstonjennifer useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT clancyrichard useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT mcgregoriain useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT brunoraimondo useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT lintzerisnick useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT montebellomark useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT lukszajennifer useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT bowmanjenny useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT phungnghi useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT allsopdave useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients AT dunlopadrianj useandeffectsofsyntheticcannabinoidreceptoragonistsbynewsouthwalescannabistreatmentclients |